Analysts’ Top Healthcare Picks: FWP, RARE

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Forward Pharma AS (NASDAQ: FWP), Ultragenyx (NASDAQ: RARE) and Blueprint Medicines (NASDAQ: BPMC) with bullish sentiments.

Forward Pharma AS (NASDAQ: FWP)

JMP Securities analyst Jason Butler reiterated a Buy rating on Forward Pharma AS (NASDAQ: FWP) today. The company’s shares opened today at $21.20.

According to TipRanks.com, Butler is a 4-star analyst with an average return of 3.9% and a 49.3% success rate. Butler covers the Healthcare sector, focusing on stocks such as Flamel Technologies S.A., Intra-Cellular Therapies, and ACADIA Pharmaceuticals.

Currently, the analyst consensus on Forward Pharma AS is Moderate Buy and the average price target is $40, representing an 88.7% upside.

In a report issued on November 23, Leerink Swann also reiterated a Buy rating on the stock with a $44 price target.
Ultragenyx (NASDAQ: RARE)

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on Ultragenyx (NASDAQ: RARE). The company’s shares opened today at $79.29.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 3.8% and a 45.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $95.20, representing a 20.1% upside.

In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $96 price target.
Blueprint Medicines (NASDAQ: BPMC)

JMP Securities analyst Michael King reiterated a Buy rating on Blueprint Medicines (NASDAQ: BPMC) today. The company’s shares opened today at $30.21.

According to TipRanks.com, King is a 1-star analyst with an average return of -1.3% and a 42.7% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.

Currently, the analyst consensus on Blueprint Medicines is Strong Buy and the average price target is $41, representing a 35.7% upside.

In a report issued on November 29, Canaccord Genuity also reiterated a Buy rating on the stock with a $35 price target.